Cronos (TSX:CRON) Stock: $0 or $30?

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) stock has been a wild ride, but if you’re patient, the company could quickly triple your investment.

| More on:
Question marks in a pile

Image source: Getty Images

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) is a millionaire-maker stock. The only problem is that it’s also a millionaire-destroyer stock. It all depends on timing.

In 2016, shares traded at $0.20. At the start of 2019, they touched $30. In just three years, a $5,000 investment became $750,000.

Then the cannabis bear market of 2019 occurred. The industry lost billions of dollars in value seemingly overnight. Cronos stock wasn’t spared, losing 60% in a matter of months. The coronavirus pandemic of 2020 only added to the pressure. Today, shares trade at $10 apiece.

It’s been a wild ride, but there’s reason to be optimistic. Many analysts believe Cronos is primed to retest its former highs. That result would triple the value of your investment.

Others aren’t so sure. The industry is still dealing with the onslaught of commoditization. Capital, meanwhile, is proving much more difficult to source. There’s a chance we could see a rash of cannabis bankruptcies before the year is done.

How will Cronos stock fare? Will shares zoom higher to $30, or might equity holders lose everything?

Bet on volatility

Here’s one thing to bet on: volatility. Despite years of advancements, the cannabis market is still in its early innings.

The tobacco and oil industries provide great insight into this evolution. At the start of both bonanzas, hundreds of operators flooded the market. Over time, however, both industries consolidated heavily. Today, we have several oil and tobacco companies worth more than $100 billion.

Tobacco and oil are commodities. So is cannabis. Pricing will rise and fall as supply and demand fluctuates. Profitability could double or triple in a single year, only to collapse the next. These shifts have contributed heavily to Cronos’ dramatic peaks and valleys.

While the pot market will remain volatile, that doesn’t mean every company will be impacted equally. In fact, there’s reason to believe the Cronos is building a business that can sidestep much of this turmoil.

As with tobacco, the key lies in the branding. There’s a reason why companies like Altria Group Inc (NYSE:MO) can sell commodified goods for a big mark-up. If consumers love your brand, they’ll pay up.

Own Cronos stock

There’s a ton of reason to believe that Cronos will emulate Altria’s success. How do I know? Altria already showed their cards, investing $1.8 billion into the pot producer.

The company now owns 45% of Cronos, with warrants that eventually allow it to take full control. This is an exclusive partnership. If Altria wants to profit from pot, it will be through its Cronos investment.

The entirety of CRON stock is now valued at just $3.5 billion. That’s incredible given that the business still has $1.8 billion in cash on the books. The underlying marijuana business is worth less than the company’s cash balance!

With so much liquidity and a long-term, deep-pocketed partner, Cronos stock isn’t going to zero anytime soon. In fact, this stock will likely lead the industry when conditions turn around. Altria is a proven branding machine. Its Marlboro brand, for example, helps it achieve a 50% market share in the U.S. for cigarettes.

How much would Cronos be worth if it commanded a 50% market share for cannabis? Cowen Inc projects the North American market to approach $100 billion in sales by 2030.

Even at a one-times-sales valuation, Cronos stock would hit $140. That’s 14 times upside!

If you want to bet on pot, this is your best chance yet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »